IASO Bio Announces NMPA Approval of IND Application for IASO-782 for Treatment of New Indication — Systemic Lupus Erythematosus (SLE)

Posted on by

SHANGHAI, NANJING, China and SAN JOSE, Calif. , July 25, 2024 /PRNewswire/ — IASO Biotechnology (“IASO Bio”), a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing innovative cell therapy and antibody products, hereby announces that the…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.